So Yeon Kim
@Sokim_33
Thoracic oncology | Phase I @YaleCancer | @MontefioreNYC alum | @TuftsMedicalCtr alum | @Princeton alum
ID:1303401698237517825
08-09-2020 18:36:01
22 Tweet
179 Takipçi
247 Takip Edilen
The efficacy of #immunotherapy is mainly attributed to reactivation of CD8+ T cells that specifically recognize tumour antigens in a MHC-I-context. There is new evidence that CD4+ T cells can contribute to antitumour immunity, independent of their role as helpers and regulators…
An analysis by So Yeon Kim Amin Nassar, MD & colleagues of treatment options for patients with stage III unresectable EGFR mutant #NSCLC showed consolidation EGFR TKI therapy yielded significantly longer disease free survival than durvalumab #ASCO23 #lcsm Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp
BFAST but be smart! Roy Herbst & So Yeon Kim discuss results of a phase III trial evaluating blood-based tumor mutational burden in patients with treatment-naive advanced-stage #NSCLC in @NatureRevCancer. #lcsm OncoAlert Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp
nature.com/articles/s4157…
Credits to the whole team! Balazs Halmos Jun Yin Stephen V Liu, MD Haiying Cheng Patrick C. Ma, MD Chul Kim Karen Reckamp, MD, MS @dipeshuprety4 Misako Nagasaka
Extensive characterization of #METex14 NSCLC in #JTOCRR by Drs. So Yeon Kim Balazs Halmos. Included 21582 samples tested with NGS: METex14 seen in 533 (2.5%). Analysis noted common co-alterations in MDM2, HMGA2, CDK4 more common in MET altered vs wild type.
jtocrr.org/article/S2666-…